法国COVID-19相关ARDS的超低潮气量通气(VT4COVID):一项多中心、开放标签、平行组随机试验
这项在法国10个ICU进行的多中心、开放标签、平行组随机试验纳入215例COVID-19相关ARDS患者(PaO2/FiO2≤150 mmHg,已接受有创机械通气且VT≤6.0 mL/kg预测体重,持续静脉镇静),随机1:1接受超低潮气量(ULTV,目标VT 4.0 mL/kg预测体重)或低潮气量(LTV,目标VT 6.0 mL/kg预测体重)。主要终点为基于90天全因死亡率和60天存活者无呼吸机天数的排名复合评分,ULTV组非匹配胜率0.85(95%CI 0.60-1.19),p=0.38,无显著差异。90天死亡率ULTV组44%(46/105)vs LTV组39%(43/109),绝对差4%(-9至18),p=0.52。ULTV组前28天严重呼吸性酸中毒发生率显著更高(33% vs 13%,绝对差20%,95%CI 9-31,p=0.0004)。结论不支持在COVID-19相关ARDS患者中系统使用ULTV。
要点
- 在COVID-19相关中重度ARDS(PaO2/FiO2≤150 mmHg)患者中,ULTV(目标VT 4.0 mL/kg预测体重)与LTV(目标VT 6.0 mL/kg预测体重)的主要复合终点无显著差异:非匹配胜率0.85(95%CI 0.60-1.19),p=0.38。
- 90天全因死亡率ULTV组44%(46/105)vs LTV组39%(43/109),绝对差4%(95%CI -9至18),p=0.52,无显著差异。
- ULTV组前28天严重呼吸性酸中毒发生率显著高于LTV组:33%(35/105)vs 13%(14/109),绝对差20%(95%CI 9至31),p=0.0004。
- 作者结论:这些发现不支持在COVID-19相关ARDS患者中系统使用ULTV。
适用人群与场景
- 年龄18岁或以上,因COVID-19(RT-PCR确诊)接受有创机械通气,符合柏林定义ARDS,PaO2/FiO2≤150 mmHg,潮气量(VT)≤6.0 mL/kg预测体重,并接受持续静脉镇静的患者。
- 研究在法国10个ICU进行。
诊断标准与关键阈值
- ARDS诊断依据柏林定义。
- 纳入标准包括PaO2/FiO2≤150 mmHg,VT≤6.0 mL/kg预测体重。
- 干预目标:ULTV组VT目标4.0 mL/kg预测体重;LTV组VT目标6.0 mL/kg预测体重。
处置流程与药物剂量
- ULTV组(干预组):机械通气目标潮气量4.0 mL/kg预测体重。
- LTV组(对照组):机械通气目标潮气量6.0 mL/kg预测体重。
红旗征与不能漏的情况
- ULTV组前28天严重呼吸性酸中毒发生率显著高于LTV组(33% vs 13%,绝对差20%,95%CI 9-31,p=0.0004)。
研究设计与关键结果
- 研究类型:多中心、开放标签、平行组随机试验,在法国10个ICU进行,2020年4月15日至2021年4月13日纳入220例患者,排除5例(2%),215例随机分组(ULTV组106例[49%],LTV组109例[51%]);女性58例(27%),男性157例(73%),中位年龄68岁(IQR 60-74)。
- 214例完成随访(ULTV组1例失访)并纳入改良意向性治疗分析。
- 主要终点:基于90天全因死亡率和60天存活者无呼吸机天数的排名复合评分,ULTV组非匹配胜率0.85(95%CI 0.60-1.19),p=0.38,无显著差异。
- 90天死亡率:ULTV组44%(46/105)vs LTV组39%(43/109),绝对差4%(95%CI -9至18),p=0.52。
- 前28天严重呼吸性酸中毒发生率:ULTV组33%(35/105)vs LTV组13%(14/109),绝对差20%(95%CI 9至31),p=0.0004。
证据类型、等级与局限
- 证据类型:多中心、开放标签、平行组随机试验;未提及证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:这些发现不支持在COVID-19相关ARDS患者中系统使用ULTV。
- 对于中重度COVID-19相关ARDS患者,使用ULTV(目标VT 4.0 mL/kg预测体重)较LTV(目标VT 6.0 mL/kg预测体重)未改善主要复合终点,且与严重呼吸性酸中毒发生率升高相关(33% vs 13%,绝对差20%,95%CI 9-31,p=0.0004)。
指南或共识出处
- Lancet Respir Med发表的VT4COVID试验(NCT04349618)。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: COVID-19-related acute respiratory distress syndrome (ARDS) is associated with a high mortality rate and longer mechanical ventilation. We aimed to assess the effectiveness of ventilation with ultra-low tidal volume (ULTV) compared with low tidal volume (LTV) in patients with COVID-19-related ARDS.
METHODS: This study was a multicentre, open-label, parallel-group, randomised trial conducted in ten intensive care units in France. Eligible participants were aged 18 years or older, received invasive mechanical ventilation for COVID-19 (confirmed by RT-PCR), had ARDS according to the Berlin definition, a partial pressure of arterial oxygen to inspiratory oxygen fraction (PaO2/FiO2) ratio of 150 mm Hg or less, a tidal volume (VT) of 6·0 mL/kg predicted bodyweight or less, and received continuous intravenous sedation. Patients were randomly assigned (1:1) using randomisation blocks to receive ULTV (intervention group) aiming for VT of 4·0 mL/kg predicted bodyweight or LTV (control group) aiming for VT 6·0 mL/kg predicted bodyweight. Participants, investigators, and outcome assessors were not masked to group assignment. The primary outcome was a ranked composite score based on all-cause mortality at day 90 as the first criterion and ventilator-free days among patients alive at day 60 as the second criterion. Effect size was computed with the unmatched win ratio, on the basis of pairwise prioritised comparison of primary outcome components between every patient in the ULTV group and every patient in the LTV group. The unmatched win ratio was calculated as the ratio of the number of pairs with more favourable outcome in the ULTV group over the number of pairs with less favourable outcome in the ULTV group. Primary analysis was done in the modified intention-to-treat population, which included all participants who were randomly assigned and not lost to follow-up. This trial is registered with ClinicalTrials.gov, NCT04349618.
FINDINGS: Between April 15, 2020, and April 13, 2021, 220 patients were included and five (2%) were excluded. 215 patients were randomly assigned (106 [49%] to the ULTV group and 109 [51%] to the LTV group). 58 (27%) patients were female and 157 (73%) were male. The median age was 68 years (IQR 60-74). 214 patients completed follow-up (one lost to follow-up in the ULTV group) and were included in the modified intention-to-treat analysis. The primary outcome was not significantly different between groups (unmatched win ratio in the ULTV group 0·85 [95% CI 0·60 to 1·19]; p=0·38). 46 (44%) of 105 patients in the ULTV group and 43 (39%) of 109 in the LTV group died by day 90 (absolute difference 4% [-9 to 18]; p=0·52). The rate of severe respiratory acidosis in the first 28 days was higher in the ULTV group than in the LTV group (35 [33%] vs 14 [13%]; absolute difference 20% [95% CI 9 to 31]; p=0·0004).
INTERPRETATION: In patients with moderate-to-severe COVID-19-related ARDS, there was no significant difference with ULTV compared with LTV in the composite score based on mortality and ventilator-free days among patients alive at day 60. These findings do not support the systematic use of ULTV in patients with COVID-19-related ARDS.
FUNDING: French Ministry of Solidarity and Health and Hospices Civils de Lyon.
参考来源
- Richard JC, Terzi N, Yonis H, et al. Ultra-low tidal volume ventilation for COVID-19-related ARDS in France (VT4COVID): a multicentre, open-label, parallel-group, randomised trial. Lancet Respir Med. 2023. PMID: 37453445. doi:10.1016/S2213-2600(23)00221-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。